BMO: IAMGOLD’s Review Of Cote Operations Expected To Be Negative

On April 18, BMO Capital Markets lowered their 12-month price target and downgraded IAMGOLD Corporation (TSX: IMG). BMO now has a $2.75 12-month price target, down from $4.00, and has a market perform rating, which was lowered from outperform. BMO says that this downgrade comes after doing a review of their estimates as well as a review “on valuation as IAMGOLD share prices have appreciated YTD,” given the equity is up 19% year to date.

IAMGOLD currently has 10 analysts covering the stock with an average 12-month price target of C$4.10. Out of the 10 analysts, 2 have buy ratings, 7 have hold ratings and 1 analyst has a sell rating on the stock. The highest 12-month price target comes in at C$6.50, which represents a 39% upside to the current stock price.

First, BMO believes that the Côté review is negative. IAMGOLD currently is reviewing the project scope and budget, which is expected to be released in the second quarter of this year. They believe that the results will be negative versus IAMGOLD’s guidance. BMO says that they are estimating the project to spend US$1.96 billion, slightly above the company’s US$1.866 billion estimates. They add, “we see risk that the budget could grow further.”

Additionally, BMO has slashed their estimates for full-year 2022 and 2023, though they expect IAMGOLD to see a strong first-quarter result due to strong results at Essakane and Rosebel/Saramacca. They admit that their previous estimates were significantly above 2022 guidance and have revised down accordingly.

Lastly, BMO believes that the agreement between Resource Capital Funds, which prompted a whole new selection of Board of Directors and an expected announcement of a new “strong permanent CEO,” will be a positive catalyst for the stock in the coming months. They do believe a weak readthrough of Côté would outweigh those positives.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Antimony Resources Expands New Discovery Following Trenching

Silver47 Kicks Off 7,000-Meter Drill Campaign at Nevada’s Hughes Project

Related News

Canaccord Reiterates Columbia Care As A Cannabis Top Pick

Columbia Care (NEO: CCHW) reported its first quarter financial results on May 17th. The company...

Thursday, May 20, 2021, 04:41:00 PM

Verano: Analysts Expect Q3 Revenues Of $219.7 Million

Verano Holdings (CSE: VRNO) announced that they will be reporting their third quarter financials before...

Monday, November 15, 2021, 10:10:00 AM

DraftKings: Canaccord Lowers Estimates Based On Planned Future Reinvestment

DraftKings Inc. (Nasdaq: DKNG) earlier this month announced its third-quarter financial results. The company announced...

Sunday, November 20, 2022, 06:29:00 PM

Cresco Labs: Canaccord Cuts Price Target On Muted Growth, Pricing Challenges

On August 17, Cresco Labs (CSE: CL) reported its second quarter financial results. The company...

Friday, August 19, 2022, 02:12:00 PM

Apple: Analysts Anticipate Q4 Revenues Of $84.85 Billion

Apple (NASDAQ: AAPL) will be reporting its fourth quarter financial results on October 27th after...

Tuesday, October 26, 2021, 05:25:00 PM